High doses of torasemide in the doctor’s practice: obvious benefits

Authors

DOI:

https://doi.org/10.22141/2307-1257.9.1.2020.196915

Keywords:

torasemide, high doses of torasimide, chronic heart disease, chronic kidney disease

Abstract

Today, torasemide is the most prescribed loop diuretic in clinical practice. Its high doses are used mainly in two clinical situations accompanied by hyperhydration: chronic heart failure (CHD) and chronic kidney disease (CKD). The latest guidelines on CHD management, 2019, have defined a clear algorithm for the use of large doses of torasemide, given that the large doses have a lasting diuretic effect. The daily dose is in the range of 50–300 mg of torasemide per day, prescribed continuously and for a long time. The clinical practice evidence demonstrates a high level of natriuretic peptide B to be usually accompanied by a large diuresis. With CKD, large doses of torasemide are in the range of 40–100 mg (200 mg) per day. Given the limitations of the renal water function, which increases proportionally with the degree of CKD, the mode and efficacy of torasemide is different from CHD. With CKD, torasemide is prescribed in doses up to 100 mg 6 days a week, the seventh is a break. When using doses of 100–200 mg, torasemide is prescribed for two days of intake — two days of break. Large doses of torasemide demonstrate high efficacy in reducing/eliminating hyperhydration in CHD and CKD. Their long-term administration reduces overall and cardiovascular mortality rates. The effect of torasemide is enhanced by the simultaneous administration of xipamide. The combination of torasemide and furosemide was determined to be impractical.

Downloads

Download data is not yet available.

References

Ivanov DD, Gozhenko AI, Savitskaya LN. Renoprotection and its association with eGFR and renal functional reserve. Počki. 2018;74):238-244. doi:10.22141/2307-1257.7.4.2018.148512.

KDIGO Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl (2011). 2012;2(5):337-414. doi:10.1038/kisup.2012.47.

Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137–155. doi:10.1002/ejhf.1369.

Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–1357. doi:10.1097/01.hjh.0000431740.32696.cc.

Bakris G, Sorrentino M. Redefining Hypertension - Assessing the New Blood-Pressure Guidelines. N Engl J Med. 2018;378(6):497–499. doi:10.1056/NEJMp1716193.

Ivanov DD, Gozhenko AI, Savitskaya LN. Renoprotection and its association with eGFR and renal functional reserve. Počki. 2018;7(4):238-244. doi:10.22141/2307-1257.7.4.2018.148512.

Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701. doi:10.2337/dci18-0033.

Ivanov DD, Rostaing L. Diuretics and advanced features of nephroprotection. Počki. 2019;8(1):2-6. doi:10.22141/2307-1257.8.1.2019.157790.

TORAFIC Investigators Group. Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. Clin Ther. 2011;33(9):1204–1213.e3. doi:10.1016/j.clinthera.2011.08.006.

Wargo KA, Banta WM. A comprehensive review of the loop diuretics: should furosemide be first line?. Ann Pharmacother. 2009;43(11):1836–1847. doi:10.1345/aph.1M177.

Shah S, Pitt B, Brater DC, et al. Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action. J Am Heart Assoc. 2017;6(10):e006135. Published 2017 Oct 5. doi:10.1161/JAHA.117.006135.

Maisel AS, Duran JM, Wettersten N. Natriuretic Peptides in Heart Failure: Atrial and B-type Natriuretic Peptides. Heart Fail Clin. 2018;14(1):13–25. doi:10.1016/j.hfc.2017.08.002.

Abraham B, Megaly M, Sous M, et al. Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure. Am J Cardiol. 2020;125(1):92–99. doi:10.1016/j.amjcard.2019.09.039.

Ter Maaten JM, Martens P, Damman K, et al. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clin Res Cardiol. 2020;10.1007/s00392-020-01598-w. doi:10.1007/s00392-020-01598-w.

Published

2021-09-08

How to Cite

Ivanov, D. (2021). High doses of torasemide in the doctor’s practice: obvious benefits. KIDNEYS, 9(1), 35–38. https://doi.org/10.22141/2307-1257.9.1.2020.196915

Issue

Section

To Help the Practitioner